Evidence of effective delivery of the human papillomavirus (HPV) vaccine through a publicly funded, school-based program: the Ontario Grade 8 HPV Vaccine Cohort Study

被引:5
|
作者
Lim, W. Ting [1 ,2 ]
Sears, Kim [3 ]
Smith, Leah M. [4 ]
Liu, Guoyuan [2 ]
Levesque, Linda E. [1 ,2 ]
机构
[1] Queens Univ, Dept Publ Hlth Sci, Kingston, ON K7L 3N6, Canada
[2] Queens Univ, Inst Clin Evaluat Sci, Kingston, ON K7L 3N6, Canada
[3] Queens Univ, Sch Nursing, Kingston, ON K7L 3N6, Canada
[4] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ H3A 1A2, Canada
来源
BMC PUBLIC HEALTH | 2014年 / 14卷
关键词
Human papillomavirus vaccines; HPV vaccine; Series completion; Adherence; Compliance; Cohort study; OLDER PATIENTS; WOMEN; COVERAGE; IMMUNOGENICITY; DISPARITIES; COMPLETION; INFECTION; EFFICACY; SAFETY;
D O I
10.1186/1471-2458-14-1029
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Proper administration of the human papillomavirus (HPV) vaccine (three doses at 0, 2, and 6 months) will likely influence the vaccine's effectiveness and the impact of vaccination programs on health outcomes. Therefore, we assessed HPV vaccine series completion and on-time dosing in Canada's largest publicly funded, school-based HPV vaccination program. Methods: Using administrative health and immunization databases, we identified a population-based cohort of girls eligible for Ontario's Grade 8 HPV vaccination program in the 2007/08-2009/10 program years who received at least one dose of the vaccine. We determined the number of doses received and calculated the percentage of girls that completed the three-dose series in Grade 8 and Grades 8-9. To assess on-time dosing, the number of days between doses 1-2, 2-3, and 1-3 was calculated and categorized (e. g., too short, on schedule, too long) based on the manufacturer's recommendations. Analyses were also stratified by program year. Results: We identified a cohort of 55,798 girls who initiated the vaccination series. Series completion was high in the Grade 8 window (81.8%) and increased by approximately 6% in Grade 9. Series completion was similar across the three program years. 70.8%, 98.5%, and 86.1% of girls were classified as 'on schedule' for dosing intervals 1-2, 2-3, and 1-3, respectively; 70.0% of girls received all three doses in perfect accordance with dosing recommendations. Stratification revealed that on-time dosing was highest in the first two years of the program (85.6% and 80.6%), but dropped to 42.1% in the 2009/10 year when H1N1 vaccination programs were prioritized. Conclusions: Our study demonstrates that delivery of the HPV vaccine through a free, school-based program is an effective method of ensuring high completion and on-time dosing, but may not be sufficient to guarantee high coverage.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Evidence of effective delivery of the human papillomavirus (HPV) vaccine through a publicly funded, school-based program: the Ontario Grade 8 HPV Vaccine Cohort Study
    W Ting Lim
    Kim Sears
    Leah M Smith
    Guoyuan Liu
    Linda E Lévesque
    [J]. BMC Public Health, 14
  • [2] THE IMPACT OF PUBLICLY FUNDED HUMAN PAPILLOMAVIRUS (HPV) VACCINATION ON CERVICAL DYSPLASIA: THE ONTARIO GRADE 8 HPV VACCINE COHORT STUDY.
    Smith, L. M.
    Kaufman, J. S.
    Strumpf, E. C.
    Levesque, L. E.
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2013, 178 (10) : 1588 - 1588
  • [3] Individual- and Regional-level determinants of Human Papillomavirus (HPV) vaccine refusal: the Ontario Grade 8 HPV vaccine cohort study
    Olivia Remes
    Leah M Smith
    Beatriz E Alvarado-Llano
    Lindsey Colley
    Linda E Lévesque
    [J]. BMC Public Health, 14
  • [4] Individual- and Regional-level determinants of Human Papillomavirus (HPV) vaccine refusal: the Ontario Grade 8 HPV vaccine cohort study
    Remes, Olivia
    Smith, Leah M.
    Alvarado-Llano, Beatriz E.
    Colley, Lindsey
    Levesque, Linda E.
    [J]. BMC PUBLIC HEALTH, 2014, 14
  • [5] A Population-Based Evaluation of a Publicly Funded, School-Based HPV Vaccine Program in British Columbia, Canada: Parental Factors Associated with HPV Vaccine Receipt
    Ogilvie, Gina
    Anderson, Maureen
    Marra, Fawziah
    McNeil, Shelly
    Pielak, Karen
    Dawar, Meena
    McIvor, Marilyn
    Ehlen, Thomas
    Dobson, Simon
    Money, Deborah
    Patrick, David M.
    Naus, Monika
    [J]. PLOS MEDICINE, 2010, 7 (05)
  • [6] Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV Vaccine Cohort Study
    Liu, Erin Y.
    Smith, Leah M.
    Ellis, Anne K.
    Whitaker, Heather
    Law, Barbara
    Kwong, Jeffrey C.
    Farrington, Paddy
    Levesque, Linda E.
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2018, 190 (21) : E648 - E655
  • [7] AN ASSESSMENT OF HUMAN PAPILLOMAVIRUS (HPV) VACCINE SERIES COMPLETION AND ON-TIME DOSING IN ONTARIO'S GRADE 8 HPV VACCINATION PROGRAM
    Smith, Leah
    [J]. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2013, 67 (10)
  • [8] Effect of human papillomavirus (HPV) vaccination on clinical indicators of sexual behaviour among adolescent girls: the Ontario Grade 8 HPV Vaccine Cohort Study
    Smith, Leah M.
    Kaufman, Jay S.
    Strumpf, Erin C.
    Levesque, Linda E.
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2015, 187 (02) : E74 - E81
  • [9] The Risk of Juvenile Arthritis Following Quadrivalent HPV Vaccination: The Ontario Grade 8 HPV Vaccine Cohort Study
    Smith, Leah M.
    Brassard, Paul
    Whitaker, Heather J.
    Farrington, Paddy
    Kwong, Jeff C.
    Levesque, Linda E.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 358 - 358
  • [10] Improving HPV vaccine delivery at school-based health centers
    Oliver, Kristin
    McCorkell, Colleen
    Pister, Ilana
    Majid, Noora
    Benkel, Denise H.
    Zucker, Jane R.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (7-8) : 1870 - 1877